Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001468223
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

### 144: Issuer Information

Name of Issuer Tango Therapeutics, Inc.

SEC File Number 001-39485

201 Brookline Ave

Suite 901

Address of Issuer Boston

MASSACHUSETTS

02215

Phone 857-320-4900

Name of Person for Whose Account the Securities are To Be Sold MVA Investors, LLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer member of group owning over 10% of the shares

### 144: Securities Information

| Title of the Class of<br>Securities To Be Sold | Name and Address of<br>the Broker   | Number of<br>Shares or<br>Other Units<br>To Be Sold | Aggregate<br>Market<br>Value | Number of<br>Shares or<br>Other Units<br>Outstanding | Approximate<br>Date of Sale | Name the<br>Securities<br>Exchange |
|--|---|---|------------------------------|--|-----------------------------|------------------------------------|
| Common Stock                                   | BofA Securities Inc.<br>1111 Ave of the Americas<br>One Bryant Park<br>New York NY 10036-<br>6706 | 60000   | 455400                       | 106718315  | 05/03/2024                  | Nasdaq                             |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

Title of the Date you Nature of Name of Person Is Date Amount of Date of Nature of

| Class        | Acquired     | Acquisition<br>Transaction | from Whom<br>Acquired   | Donor<br>Acquired | Securities<br>Acquired | Payment       | Payment * |
|--------------|--------------|----------------------------|-------------------------|-------------------|------------------------|---------------|-----------|
| Common Stock | 10/11/2022 F | Open Market<br>Purchases   | Tango Therapeutics, Inc |                   | 60000                  | 10/11/2022 Ca | ısh       |

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

| Name and Address of Seller  | Title of Securities Sold | Date of<br>Sale | Amount of<br>Securities<br>Sold | <b>Gross Proceeds</b> |
|---|--------------------------|-----------------|---------------------------------|-----------------------|
| MVA Investors, LLC<br>12860 El Camino Real, Suite 300<br>San Diego CA 92130 | Common Stock             | 05/01/2024      | 75000                           | 577500                |
| MVA Investors, LLC<br>12860 El Camino Real, Suite 300<br>San Diego CA 92130 | Common Stock             | 05/02/2024      | 75000                           | 546000                |

# 144: Remarks and Signature

Remarks Aggregate Market Value as of 05/02/2024

Date of Notice 05/03/2024

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Aaron Davis, Chief Executive Officer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)